Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Agile operations drive enrollment in COVID-19 treatment studies
A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.
genetic seizure disorder in children.
Patient recruitment & retention services
A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.
support patient enrollment.
In-Home Services: Patient centric practices
Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.
Agile operations drive enrollment in COVID-19 treatment studies
ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.
High-performing sites during COVID-19 in Women’s Health
A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.
Beating patient recruitment target with enhanced patient experience
Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.
Overcoming the challenges of COVID-19 clinical trial conditions
A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=lNlx63Nb "Accellacare - Staff (31)"){kind=icon}
High performing sites in cardiovascular study
Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=4UCVbMUt "Accellacare - Staff (30)"){kind=icon}
Exceeding expectations in a c. diff vaccine study
Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.
by a large pharma sponsor and ICON.
Digital solutions to reduce risk potential for six-study dermatology programme
A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.
Digital solutions for an evolving COVID-19 environment
One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.
Optimising Biosimilar Development
ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.